Corrigendum to "Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life" [Eur J Cancer 176 (2022) 88-99].
- DOI
- 10.1016/j.ejca.2025.115236
- Published
- 2025-01-20
- Container
- Eur J Cancer
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2025.115236,
title = {Corrigendum to "Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life" [Eur J Cancer 176 (2022) 88-99].},
author = {Schulz TU and Zierold S and Sachse MM and Pesch G and Tomsitz D and Schilbach K and Kähler KC and French LE and Heinzerling L.},
year = {2025},
journal = {Eur J Cancer},
doi = {10.1016/j.ejca.2025.115236},
url = {https://doi.org/10.1016/j.ejca.2025.115236}
}RIS
TY - JOUR TI - Corrigendum to "Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life" [Eur J Cancer 176 (2022) 88-99]. AU - Schulz TU AU - Zierold S AU - Sachse MM AU - Pesch G AU - Tomsitz D AU - Schilbach K AU - Kähler KC AU - French LE AU - Heinzerling L. PY - 2025 JO - Eur J Cancer DO - 10.1016/j.ejca.2025.115236 UR - https://doi.org/10.1016/j.ejca.2025.115236 ER -
APA
TU, S., S, Z., MM, S., G, P., D, T., K, S., KC, K., LE, F., & L., H. (2025). Corrigendum to "Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life" [Eur J Cancer 176 (2022) 88-99].. Eur J Cancer. https://doi.org/10.1016/j.ejca.2025.115236
Source records
- europe-pmc · retrieved 2026-09-26T19:30:38.770Z